Study Name:
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets (OCEAN-1)
Targeted Disease(s):
Pulmonary Fibrosis
Purpose of Study:
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
Study Dates:
June 29, 2026 - January 1, 2028
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Trevi Therapeutics
Sponsors:
Trevi Therapeutics
ClinicalTrails.gov Identifier:
NCT07671911
